Raymond James Financial’s Alnylam Pharmaceuticals ALNY Stock Holding History

Raymond James Financial’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$130M	Buy	406,956 +18,251	+5%	+$6.21M	0.04%	409
2025 Q4	$154M	Buy	388,705 +11,411	+3%	+$5.05M	0.05%	349
2025 Q3	$172M	Buy	377,294 +106,844	+40%	+$43.5M	0.06%	309
2025 Q2	$88.2M	Buy	270,450 +1,480	+0.6%	+$410K	0.03%	520
2025 Q1	$72.6M	Sell	268,970 -8,516	-3%	-$2.19M	0.03%	544
2024 Q4	$65.3M	Buy	+277,486	New	+$73M	0.02%	591

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Raymond James Financial's ALNY Position: Q1 2026 in Review

Raymond James Financial increased its Alnylam Pharmaceuticals (ALNY) stake by 4.7% in Q1 2026, buying an estimated $6.21M and bringing the position to 406,956 shares worth $130M. The position accounts for 0.04% of the portfolio, ranked #409.

Raymond James Financial first reported a position in ALNY in Q4 2024 and has held it in 6 quarters since. The position peaked at $172M in Q3 2025. 789 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

Raymond James Financial held 406,956 shares of Alnylam Pharmaceuticals worth $130M as of Q1 2026.
Raymond James Financial bought 18,251 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $6.21M.
Alnylam Pharmaceuticals made up 0.04% of Raymond James Financial's portfolio in Q1 2026, its #409 holding.
Raymond James Financial first reported a position in Alnylam Pharmaceuticals in Q4 2024 and has held it in 6 quarters since.
Raymond James Financial's Alnylam Pharmaceuticals position peaked at $172M in Q3 2025.
789 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on Raymond James Financial's 13F filing for Q1 2026, filed 14 May 2026.